Patients who engage fully with nutritional counseling, follow activity guidance, and attend follow-ups tend to see more consistent outcomes
So far, large studies have not shown a consistent or significant increase in pancreatitis risk with semaglutide, tirzepatide, or other GLP-1s compared to placebo
But theory and practice are not the same thing
Stopping semaglutide abruptly often leads to rapid rebound, with reports of a 50% increase in appetite within the first week, and about 70% of patients experience weight regain after abrupt discontinuation
These medications are quite expensive if theyre not covered by insurance, and a lot of people cant afford that. Foundayo and Zepbound now covered for millions of Americans
Thats why we donate 10% of all our profits to veteran-focused charities